The ABPI’s “manifesto for investment, health and growth” says that the new government to be elected later this year must ensure that investment in new medicines and research accelerates future innovation and attracts more R&D to the UK.
Shortly after the UK Labour Party disclosed its plans for boosting the country’s life sciences sector, the Association of the British Pharmaceutical Industry published its own proposals outlining what a new government must do to “make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.”
With a general election expected sometime in the second half of this year, the ABPI has welcomed Labour’s life science...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
